Blog
RSS FeedPosted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 23 Feb 2019
When biotechs get breakthrough therapy status, Mr. Market yawns
23 February 2019 - As a biotech consultant, I’ve heard many CEO’s tell me that a “drumbeat of news” is ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...
Posted by Michael Wonder on 07 Feb 2019
Cigna eclipses 50% in value-based care pay to providers
7 February 2019 - Cigna says it’s paying more than half of its reimbursements to medical care providers in its ...
Posted by Michael Wonder on 23 Jan 2019
Discrete choice experiments in health economics: past, present and future
23 January 2019 - Discrete choice experiments are increasingly advocated as a way to quantify preferences for health. ...
Posted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 09 Jan 2019
Price drugs according to what they do
8 January 2019 - A simple reform to improve outcomes and control costs. ...
Posted by Michael Wonder on 19 Dec 2018
Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score
19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...
Posted by Michael Wonder on 13 Dec 2018
ICER describes for patients and policy makers why the QALY is considered the best way to reward the care that improves patients’ lives
12 December 2018 - ICER reiterates its commitment to equality and will highlight measures of cost-effectiveness that value any extension of ...
Posted by Michael Wonder on 13 Dec 2018
Value-based pricing and reimbursement: still more promise than reality
13 December 2018 - Value in health care is measured in terms of the patient outcomes achieved per dollars spent. As ...
Posted by Michael Wonder on 29 Nov 2018
Amgen cuts Repatha’s price by 60 percent. Will value-based pricing support value-based patient access?
28 November 2018 - Recently, Amgen announced a 60% reduction in the list price of its PCSK9 drug Repatha for patients ...
Posted by Michael Wonder on 26 Nov 2018
We're paying $834 million more for health insurance but getting less
26 November 2018 - Australians paid $834 million more for health insurance in 2017-18 compared to the year before, despite ...